Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of niraparib in men with metastatic castration-resistant prostate cancer and DNA repair defects
MOH_2018-03-19_002107Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of niraparib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Janssen Pharmaceutical. Started May 2017; status: completed.
02
Drugs
niraparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on MOH_2018-03-19_002107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-03-19_002107.